Literature DB >> 23212129

Accurate sensitivity of quantum dots for detection of HER2 expression in breast cancer cells and tissues.

Akram-Sadat Tabatabaei-Panah1, Mahmood Jeddi-Tehrani, Roya Ghods, Mohammad-Mehdi Akhondi, Nazanin Mojtabavi, Ahmad-Reza Mahmoudi, Ebrahim Mirzadegan, Sorour Shojaeian, Amir-Hassan Zarnani.   

Abstract

Here we introduce novel optical properties and accurate sensitivity of Quantum dot (QD)-based detection system for tracking the breast cancer marker, HER2. QD525 was used to detect HER2 using home-made HER2-specific monoclonal antibodies in fixed and living HER2(+) SKBR-3 cell line and breast cancer tissues. Additionally, we compared fluorescence intensity (FI), photostability and staining index (SI) of QD525 signals at different exposure times and two excitation wavelengths with those of the conventional organic dye, FITC. Labeling signals of QD525 in both fixed and living breast cancer cells and tissue preparations were found to be significantly higher than those of FITC at 460-495 nm excitation wavelengths. Interestingly, when excited at 330-385 nm, the superiority of QD525 was more highlighted with at least 4-5 fold higher FI and SI compared to FITC. Moreover, QDs exhibited exceptional photostability during continuous illumination of cancerous cells and tissues, while FITC signal faded very quickly. QDs can be used as sensitive reporters for in situ detection of tumor markers which in turn could be viewed as a novel approach for early detection of cancers. To take comprehensive advantage of QDs, it is necessary that their optimal excitation wavelength is employed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23212129     DOI: 10.1007/s10895-012-1147-9

Source DB:  PubMed          Journal:  J Fluoresc        ISSN: 1053-0509            Impact factor:   2.217


  24 in total

1.  HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.

Authors:  Marilyn A Owens; Bruce C Horten; Moacyr M Da Silva
Journal:  Clin Breast Cancer       Date:  2004-04       Impact factor: 3.225

2.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

Review 3.  Core/Shell semiconductor nanocrystals.

Authors:  Peter Reiss; Myriam Protière; Liang Li
Journal:  Small       Date:  2009-02       Impact factor: 13.281

Review 4.  Quantum dots versus organic dyes as fluorescent labels.

Authors:  Ute Resch-Genger; Markus Grabolle; Sara Cavaliere-Jaricot; Roland Nitschke; Thomas Nann
Journal:  Nat Methods       Date:  2008-09       Impact factor: 28.547

5.  Quantum dot bioconjugates for ultrasensitive nonisotopic detection.

Authors:  W C Chan; S Nie
Journal:  Science       Date:  1998-09-25       Impact factor: 47.728

6.  Fluoroimmunoassays using antibody-conjugated quantum dots.

Authors:  Ellen R Goldman; Hedi Mattoussi; George P Anderson; Igor L Medintz; J Matthew Mauro
Journal:  Methods Mol Biol       Date:  2005

7.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

8.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

Review 9.  Early detection of breast cancer: new biomarker tests on the horizon?

Authors:  Aparna C Jotwani; Julie R Gralow
Journal:  Mol Diagn Ther       Date:  2009-12-01       Impact factor: 4.074

10.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

Authors:  S Paik; R Hazan; E R Fisher; R E Sass; B Fisher; C Redmond; J Schlessinger; M E Lippman; C R King
Journal:  J Clin Oncol       Date:  1990-01       Impact factor: 44.544

View more
  4 in total

Review 1.  Quantum dots for quantitative imaging: from single molecules to tissue.

Authors:  Tania Q Vu; Wai Yan Lam; Ellen W Hatch; Diane S Lidke
Journal:  Cell Tissue Res       Date:  2015-01-27       Impact factor: 5.249

Review 2.  HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment.

Authors:  Leopoldo Sitia; Marta Sevieri; Lorena Signati; Arianna Bonizzi; Arianna Chesi; Francesco Mainini; Fabio Corsi; Serena Mazzucchelli
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

3.  Incorporating gold nanoclusters and target-directed liposomes as a synergistic amplified colorimetric sensor for HER2-positive breast cancer cell detection.

Authors:  Yu Tao; Mingqiang Li; Bumjun Kim; Debra T Auguste
Journal:  Theranostics       Date:  2017-02-08       Impact factor: 11.556

4.  Isolation and partial characterization of human amniotic epithelial cells: the effect of trypsin.

Authors:  Meraj Tabatabaei; Nariman Mosaffa; Shohreh Nikoo; Mahmood Bozorgmehr; Roya Ghods; Somaieh Kazemnejad; Simin Rezania; Bahareh Keshavarzi; Soheila Arefi; Fahimeh Ramezani-Tehrani; Ebrahim Mirzadegan; Amir-Hassan Zarnani
Journal:  Avicenna J Med Biotechnol       Date:  2014-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.